Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
A-dmDT390-bisFv(National Institutes of Health) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
A-dmDT390-bisFv(National Institutes of Health): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Chronic Spontaneous Urticaria Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Chronic Spontaneous Urticaria clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Rugocrixan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Rugocrixan: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Pemphigus Vulgaris Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Pemphigus Vulgaris clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
ICT-01 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
ICT-01: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Polymyalgia Rheumatica Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Polymyalgia Rheumatica clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Giant Cell Arteritis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Giant Cell Arteritis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Perzebertinib Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Perzebertinib: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
PTPN22 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
17 July 2026
A visual target evaluation report for PTPN22, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
ANCA-Associated Vasculitis Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 ANCA-Associated Vasculitis clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white…
Latest Hotspot
8 min read
Gemlapodect Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Gemlapodect: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Idiopathic Inflammatory Myopathies Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Idiopathic Inflammatory Myopathies clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development…